Healthcare - Biotechnology - NASDAQ - US
$ 189.23
-2.1 %
$ 21 B
Market Cap
-23.08
P/E
BALANCE SHEET
5.81 B
ASSETS
2.27 B
LIABILITIES
3.54 B
EQUITY
BALANCE SHEET DECOMPOSITION
Balance Sheet Decomposition
BeiGene, Ltd.
| Current Assets | 4.2 B |
| Cash & Short-Term Investments | 3.17 B |
| Receivables | 396 M |
| Other Current Assets | 633 M |
| Non-Current Assets | 1.6 B |
| Long-Term Investments | 89.6 M |
| PP&E | 1.42 B |
| Other Non-Current Assets | 92.9 M |
| Current Liabilities | 1.81 B |
| Accounts Payable | 315 M |
| Short-Term Debt | 732 M |
| Other Current Liabilities | 763 M |
| Non-Current Liabilities | 458 M |
| Long-Term Debt | 220 M |
| Other Non-Current Liabilities | 238 M |
Balance Sheet
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Cash & Cash Equivalents | 3 171.8 | 3 869.6 | 4 375.7 | 1 382.0 | 618.0 | 712.9 | 239.6 | 87.5 | 17.9 | 13.9 | 3.9 |
| Short Term Investments | 2.6 | 665.3 | 2 242.0 | 3 268.7 | 364.7 | 1 068.5 | 597.9 | 280.7 | 82.6 | 30.5 | 0 |
| Receivables | 395.9 | 173.2 | 500.2 | 79.7 | 70.9 | 52.8 | 29.4 | 0 | 0 | 0 | 0 |
| Inventory | 416.1 | 282.3 | 242.6 | 89.3 | 28.6 | 16.2 | 10.9 | 0 | 0 | 0 | 0 |
| Other Current Assets | 205.5 | 288.2 | 253.1 | 141.0 | 90.5 | 93.4 | 45.5 | 10.4 | 5.8 | 2.8 | 0.5 |
| Total Current Assets | 4 203.4 | 4 713.5 | 7 613.9 | 4 960.7 | 1 172.7 | 1 943.8 | 913.5 | 374.4 | 106.3 | 47.2 | 4.4 |
| PP&E | 1 419.4 | 845.9 | 686.7 | 446.3 | 313.1 | 194.2 | 62.6 | 26.0 | 6.6 | 5.9 | 7.1 |
| Intangible Assets | 57.1 | 94.6 | 103.3 | 53.7 | 52.8 | 52.2 | 19.7 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0 | 0 | 0 | 0 |
| Long Term Investments | 89.6 | 91.8 | 100.8 | 49.3 | 33.2 | 16.5 | 0 | 0 | 0 | 0 | 0 |
| Other Long Term Assets | 35.7 | (186.5) | 30.7 | 24.6 | 2.5 | 13.2 | 42.9 | 4.7 | 3.9 | 0.5 | 0.3 |
| Other Assets | 0 | 819.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 5 805.3 | 6 379.3 | 8 645.9 | 5 600.8 | 1 612.3 | 2 249.7 | 1 046.5 | 405.8 | 116.8 | 53.6 | 11.8 |
| LIABILITIES | |||||||||||
| Accounts Payable | 315.1 | 294.8 | 168.0 | 232.0 | 122.5 | 113.3 | 69.8 | 12.0 | 9.0 | 2.8 | 2.1 |
| Short Term Debt | 732.3 | 377.1 | 471.4 | 362.8 | 21.6 | 8.7 | 9.2 | 0 | 14.6 | 0.3 | 20.0 |
| Other Current Liabilities | 739.8 | 538.8 | 705.6 | 445.7 | 143.1 | 92.4 | 49.6 | 22.3 | 11.6 | 10.3 | 9.7 |
| Total Current Liabilities | 1 810.1 | 1 018.0 | 1 599.6 | 1 075.2 | 286.0 | 246.5 | 150.0 | 35.1 | 35.2 | 13.4 | 31.7 |
| Long Term Debt | 219.9 | 243.7 | 245.2 | 213.1 | 266.5 | 189.7 | 155.5 | 17.3 | 6.2 | 13.5 | 15.2 |
| Deferred Tax Income | 16.5 | 16.0 | 14.2 | 10.8 | 10.5 | 11.1 | 0.4 | 0 | (1.0) | 0 | 0 |
| Other Liabilities | 221.5 | 225.7 | 277.4 | 432.5 | 24.4 | 1.1 | 56.8 | 0.6 | 1.1 | 1.0 | 3.6 |
| Total Liabilities | 2 267.9 | 1 995.9 | 2 403.0 | 1 731.5 | 633.9 | 496.0 | 362.2 | 405.8 | 116.8 | 27.9 | 50.5 |
| EQUITY | |||||||||||
| Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 79 K | 77 K | 59 K | 52 K | 12 K | 23 K | 9 K |
| Retained Earnings | (7 962.1) | (7 080.3) | (4 966.1) | (3 552.7) | (1 955.8) | (1 007.2) | (330.5) | (237.4) | (118.2) | (61.1) | (42.8) |
| Other Accumulative Comprehensive Income/Loss | (99.4) | (77.4) | 17.9 | 6.9 | (8.0) | 1.5 | (0.5) | (0.9) | (1.8) | 100 K | 0.3 |
| Total Equity | 3 537.3 | 4 383.4 | 6 243.0 | 3 869.2 | 994.5 | 1 768.1 | 698.7 | 352.9 | (101.8) | 25.8 | (37.0) |
| Total Liabilities and Equity | 5 805.3 | 6 379.3 | 8 645.9 | 5 600.8 | 1 612.3 | 2 249.7 | 1 046.5 | 405.8 | 116.8 | 53.6 | 11.8 |
| SHARES OUTSTANDING | |||||||||||
| Common Shares Outstanding | 104.4 | 103.1 | 92.8 | 83.5 | 60.1 | 55.4 | 45.5 | 39.7 | 31.5 | 52.7 | 52.7 |